G E Lou - Gynecology

Author Information

G. Lou is affiliated with the Department of Gynecology at The Affiliated Tumor Hospital of Harbin Medical University, located in Harbin, Heilongjiang, China. Dr. Lou is a notable figure in the field of gynecology, particularly focusing on ovarian cancer research.

Research Contributions

Dr. G. Lou has made significant contributions to the field of ovarian cancer research. In 2022 alone, Dr. Lou has co-authored several influential papers, including studies on the efficacy of Olaparib and Fuzuloparib as maintenance therapies for platinum-sensitive relapsed ovarian cancer, as well as investigations into the molecular traits of epithelial ovarian cancer. Other notable works include research on the repression of lncRNA PART1 in attenuating ovarian cancer cell viability and studies identifying immune-related genes for predicting prognosis and therapeutic response in ovarian cancer. These contributions have considerably advanced the understanding and treatment of ovarian cancer.

Aliases

Dr. G. Lou is also known by several aliases, including G E Lou, G Lou, and Ge Lou.

Publication and Citation Metrics

Metric	Value
Citation Count	3802
H-Index	36
Paper Count	171

Publications:

Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial.

DOI: 10.1111/ajco.13753

Year: 2022

Repression of lncRNA PART1 attenuates ovarian cancer cell viability, migration and invasion through the miR-503-5p/FOXK1 axis

DOI: 10.1186/s12885-021-09005-x

Year: 2022

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).

DOI: 10.1158/1078-0432.CCR-21-3023

Year: 2022

Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes

DOI: 10.1038/s41388-022-02277-y

Year: 2022

Risk Factors and Prognosis of Early Recurrence in Stage I–II Endometrial Cancer: A Large-Scale, Multi-Center, and Retrospective Study

DOI: 10.3389/fmed.2022.808037

Year: 2022

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

DOI: 10.1136/jitc-2021-003831

Year: 2022

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.

DOI: 10.1200/JCO.21.01511

Year: 2022

Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial

DOI: 10.1016/s0090-8258(21)00752-6

Year: 2021

Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer

DOI: 10.3389/fimmu.2021.763791

Year: 2021

An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer

DOI: 10.1158/1078-0432.CCR-20-3546

Year: 2021

Is the Exam Painful?

Why are falls relevant in gynecology?

Why are Pelvic Floor Muscles Important in Gynecology?

Is There a Connection Between Periodontal Disease and Polycystic Ovary Syndrome (PCOS)?

What is the Connection Between CGG Repeats and Premature Ovarian Insufficiency?

Why might I need a hysteroscopy?

Are There Risks Associated with Detoxification?

How does edamame affect fertility?

What topics are covered at the FIGO Congress?

How Do Relaxation Techniques Affect Fertility?

Partnered Content Networks

Relevant Topics